Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays

Yusheng Qu., Robert Kirby., Richard Davies., Ayesha Jinat., Stefano Stabilini., Bin Wu., Longchuan Yu., BaoXi Gao., and Hugo M. Vargas. (2023). Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays. Nucleic Acid Therapeutics. Nucleic Acid Therapeutics, 2022.

This publication was awarded the '2024 Technology Innovation Publication Award' by the Safety Pharmacology Society.


View
Recommended Publications
Latest Publications
The state of the art in secondary pharmacology and its impact on the safety of new medicines

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

Derek J. Leishman, Jessica Brimecombe, William Crumb, Simon Hebeisen, Steve Jenkinson, Peter J. Kilfoil, Hiroshi Matsukawa, Karim Melliti, Yusheng Qu, Journal of Pharmacological and Toxicological Methods, Volume 128, 2024, 107524, ISSN 1056-8719. DOI: 10.1007/978-3-031-52197-3

Copyright prevents linking to the article.

View All
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram